Mutations of IDH1 (isocitrate dehydrogenase 1, IDH1) can be found in glioblastoma and myeloproliferative neoplasms. Detection of IDH1 mutations may be a positive predictor of prognosis and a molecular marker for patients with glioblastoma. On the other hand, IDH1 mutations are reported to correlate with poor prognosis in myeloproliferative neoplasia. The PNAClamp ™ IDH1 mutation detection kit PNAClamp ™ IDH1 is a new member of somatic mutation detection kits using PNA-mediated PCR binding technology and can help patients choose the right drug and monitor prognosis.